Cirrhosis NASH Trials
Age – Adult (18-85)
Gender – Female, Male
Disease Type – Cirrhosis Hepatic Encephalopathy
Phase – 3
Length -72 weeks
Compensation available.
Inclusion:
– Cirrhosis with Hepatic Encephalopathy
– Medically controlled ascites or no ascites present
– West Haven Criteria <2
– Males and non-pregnant females
Exclusion:
– Allergy to Rifaximin, rifampin, rifamycin antimicrobial agent
– Receiving dialysis
– Active Cancer diagnosis
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER
STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE
SOLID DISPERSION (SSD) TABLETS FOR THE DELAY OF ENCEPHALOPATHY
DECOMPENSATION IN CIRRHOSIS (RED-C)
Age – Adult (18-85)
Gender – Female, Male
Disease Type – Cirrhosis Hepatic Encephalopathy
Phase – 3
Length -72 weeks
Compensation available.
Inclusion:
– Cirrhosis Medically controlled ascites
– West Haven Criteria <2
– Males and non-pregnant females
Exclusion:
– Allergy to Rifaximin, rifampin, rifamycin antimicrobial agent
– Receiving dialysis
– Active Cancer diagnosis
A Randomized Double-blind Placebo-controlled Phase 3
Study to Evaluate the Effect of Resmetirom on Liver-related
Outcomes in Patients with Well-compensated (Child-Pugh
A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis
(MAESTRO-NASH OUTCOMES)
Learn More
Additional Information
For more information on what current clinical trials are available at Kansas City Research Institute or additional information and how to get involved, please contact our office phone at (816)759-2574 or send by email at study@kcresearchinstitute.com.